SITESEEKER to be used for Otsuka’s therapeutics discovery programs

PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a multi-project collaboration with Otsuka Pharmaceutical Co., the world-leading pharmaceutical company dedicated to the research and development of highly-innovative drugs and diagnostics. Financial details of the agreement are not disclosed.

PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, towards disease-relevant pathways nominated by Otsuka. Novel targets identified will be further validated and characterized by Otsuka as part of its internal development pipeline, with an initial focus on gene therapy applications of identified targets.

PhoreMost’s SITESEEKER platform exploits protein shape diversity to find functionally active peptides, significantly enhancing the power of phenotypic screening and translation into therapeutic modalities.

Based on proprietary protein interference, or ‘PROTEINi®’, technology PhoreMost uses SITESEEKER to probe the entire proteome in a live cell environment for novel druggable targets linked to any chosen disease. This enables the systematic discovery of functionally active peptides which are directly linked to useful therapeutic applications.

This collaboration with Otsuka is further recognition of the power of the SITESEEKER approach to drive the identification of novel, druggable targets. We are particularly excited to be exploring not only small molecule therapeutics but also gene therapy applications of our platform.”

Dr Chris Torrance, CEO of PhoreMost

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    PhoreMost. (2020, January 21). SITESEEKER to be used for Otsuka’s therapeutics discovery programs. News-Medical. Retrieved on July 15, 2024 from https://www.news-medical.net/news/20200121/SITESEEKER-to-be-used-for-Otsukas-therapeutics-discovery-programs.aspx.

  • MLA

    PhoreMost. "SITESEEKER to be used for Otsuka’s therapeutics discovery programs". News-Medical. 15 July 2024. <https://www.news-medical.net/news/20200121/SITESEEKER-to-be-used-for-Otsukas-therapeutics-discovery-programs.aspx>.

  • Chicago

    PhoreMost. "SITESEEKER to be used for Otsuka’s therapeutics discovery programs". News-Medical. https://www.news-medical.net/news/20200121/SITESEEKER-to-be-used-for-Otsukas-therapeutics-discovery-programs.aspx. (accessed July 15, 2024).

  • Harvard

    PhoreMost. 2020. SITESEEKER to be used for Otsuka’s therapeutics discovery programs. News-Medical, viewed 15 July 2024, https://www.news-medical.net/news/20200121/SITESEEKER-to-be-used-for-Otsukas-therapeutics-discovery-programs.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
PhoreMost appoints Christian Dillon as Vice President of Biology